Genmab — December 2019
-
GENMAB-KONKURRENTER MED POSITIVE STUDIEDATA FOR KRÆFTMIDDEL - GENT
06:34
Det amerikanske medicinalselskab Bristol-Myers Squibb og biotekselskabet Bluebird kan glæde sig over positive resultater i et nyt studie med et middel mod knoglemarvskræft.Det drejer sig om et fase 2-studie med lægemiddelkandidaten bb2121, og resultaterne har levet op til studiets formål, oplyser selskaberne i en meddelelse fredag aften.
Ifølge Bloomberg News viste studiet, at mere end 80 pct. af patienterne, der
-
-
-
God morgen.
-
Mohamad Mohty
@Mohty_EBMT
·
3 t
#ASH19 Sunday thoughts at the end of the day:- BITE antibodies are likely to dominate the field rapidly and can seriously challenge the currently available CAR-T cells...https://twitter.com/Mohty_EBMT/status/1203873850045407232
-
Opvarmning:
@Genmab
·
7 t
The first presentation of pre-clinical data from #Genmab’s HexaBody
-CD38 is now available at the #ASH19 poster session in Hall B, Level 2https://twitter.com/Genmab/status/1203815064257597441 -
-
Fransk medicinalgigant køber californisk selskab i milliardhandel http://dlvr.it/RKwS9q
-
Der vist nogen som er blevet lidt nervøse for konkurrent situationen i weekenden.
-
stor omsætning på de første fem minutter.
-
CarT på ASH har kortsigtet skræmt Genmabinvestorer før.
-
Det kan også være at der bliver sat nogle nye shorts nu.
-
Ofatumumab with Hyper-cvad in Mantle cell lymphoma https://twitter.com/YAbdouMD/status/1203816507769344001
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind